1
|
Guidolin K, Ding L, Yan H, Englesakis Hba M, Chadi S, Quereshy F, Zheng G. Photodynamic Therapy for Colorectal Cancer: A Systematic Review of Clinical Research. Surg Innov 2022; 29:788-803. [PMID: 35428418 PMCID: PMC9667091 DOI: 10.1177/15533506221083545] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND Photodynamic therapy (PDT) is a therapeutic modality that can be used to ablate tumors using the localized generation of reactive oxygen species by combining a photosensitizer, light, and molecular oxygen. This modality holds promise as an adjunctive therapy in the management of colorectal cancer and could be incorporated into neoadjuvant treatment plans under the auspices of prospective clinical trials. METHODS We conducted a search of primary literature published until January 2021, based on PRISMA guidelines. Primary clinical studies of PDT for the management of colorectal cancer were included. Screening, inclusion, quality assessment, and data collection were performed in duplicate. Analyses were descriptive or thematic. RESULTS Nineteen studies were included, most of which were case series. The total number of patients reported to have received PDT for colorectal cancer was 137, almost all of whom received PDT with palliative intent. The most common photosensitizer was hematoporphyin derivative or Photofrin. The light dose used varied from 32 J/cm2 to 500 J/cm2. Complete tumor response (cure) was reported in 40%, with partial response reported in 43.2%. Symptomatic improvement was reported in 51.9% of patients. In total, 32 complications were reported, the most common of which was a skin photosensitivity reaction. CONCLUSIONS PDT for the management of colorectal cancer has not been well studied, despite promising results in early clinical case series. New, well designed, prospective clinical trials are required to establish and define the role of PDT in the management of colorectal cancer.
Collapse
Affiliation(s)
- Keegan Guidolin
- Department of Surgery, 7938University of Toronto, Toronto, ON, Canada.,Institute of Biomedical Engineering, 7938University of Toronto, Toronto, ON, Canada.,10051Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - Lili Ding
- 10051Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - Han Yan
- Department of Surgery, 7938University of Toronto, Toronto, ON, Canada
| | | | - Sami Chadi
- Department of Surgery, 7938University of Toronto, Toronto, ON, Canada.,10051Princess Margaret Cancer Centre, Toronto, ON, Canada.,7989University Health Network, Toronto, ON, Canada
| | - Fayez Quereshy
- Department of Surgery, 7938University of Toronto, Toronto, ON, Canada.,10051Princess Margaret Cancer Centre, Toronto, ON, Canada.,7989University Health Network, Toronto, ON, Canada
| | - Gang Zheng
- Department of Surgery, 7938University of Toronto, Toronto, ON, Canada.,Institute of Biomedical Engineering, 7938University of Toronto, Toronto, ON, Canada.,10051Princess Margaret Cancer Centre, Toronto, ON, Canada
| |
Collapse
|
2
|
Douillard S, Rozec B, Bigot E, Aillet L, Patrice T. Secondary reactive oxygen species production after PDT during pulmonary tumor growth in sera of nude mice. Photodiagnosis Photodyn Ther 2013; 10:62-71. [DOI: 10.1016/j.pdpdt.2012.05.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2011] [Revised: 04/04/2012] [Accepted: 05/20/2012] [Indexed: 10/28/2022]
|
3
|
Chen Z, Song T, Chen X, Wang S, Chen J. Study on the interaction between hematoporphyrin monomethyl ether and DNA and the determination of hematoporphyrin monomethyl ether using the resonance light scattering technique. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2010; 77:605-611. [PMID: 20643575 DOI: 10.1016/j.saa.2010.06.023] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2010] [Revised: 05/27/2010] [Accepted: 06/15/2010] [Indexed: 05/29/2023]
Abstract
The interaction between photosensitizer anticancer drug hematoporphyrin monomethyl ether (HMME) and ctDNA has been studied based on the decreased resonance light scattering (RLS) phenomenon. The RLS, UV-vis and fluorescence spectra characteristics of the HMME-ctDNA system were investigated. Besides, the phosphodiesters quaternary ammonium salt (PQAS), a kind of new gemini surfactant synthesized recently, was used to determine anticancer drug HMME based on the increasing RLS intensity. Under the optimum assay conditions, the enhanced RLS intensity was proportional to the concentration of HMME. The linear range was 0.8-8.4microgmL(-1), with correlation coefficient R(2)=0.9913. The detection limit was 0.014microgmL(-1). The human serum samples and urine samples were determined satisfactorily, which proved that this method was reliable and applicable in the determination of HMME in body fluid. The presented method was simple, sensitive and straightforward and could be a significant method in clinical analysis.
Collapse
Affiliation(s)
- Zhanguang Chen
- Department of Chemistry, Shantou University, Shantou, China.
| | | | | | | | | |
Collapse
|
4
|
Dunn JM, Mackenzie GD, Oukrif D, Mosse CA, Banks MR, Thorpe S, Sasieni P, Bown SG, Novelli MR, Rabinovitch PS, Lovat LB. Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy. Br J Cancer 2010; 102:1608-17. [PMID: 20461081 PMCID: PMC2883155 DOI: 10.1038/sj.bjc.6605688] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Background and aims: DNA ploidy abnormalities (aneuploidy/tetraploidy) measured by flow cytometry (FC) are strong predictors of future cancer development in untreated Barrett's oesophagus, independent of histology grade. Image cytometric DNA analysis (ICDA) is an optical technique allowing visualisation of abnormal nuclei that may be undertaken on archival tissue. Our aim was to determine the accuracy of ICDA vs FC, and evaluate DNA ploidy as a prognostic biomarker after histologically successful treatment with photodynamic therapy (PDT). Methods: Nuclei were extracted from 40 μm sections of paraffin-embedded biopsies and processed for ICDA at UCL and FC at UW using standardised protocols. Subsequently, DNA ploidy was evaluated by ICDA on a cohort of 30 patients clear of dysplasia 1 year after aminolaevulinic acid PDT for high-grade dysplasia (HGD). The results were correlated with long-term outcome. Results: In the comparative study, 93% (41 out of 44) of cases were classified identically. Errors occurred in the near-diploid region by ICDA and the tetraploid region by FC. In the cohort study, there were 13 cases of late relapse (7 cancer, 6 HGD) and 17 patients who remained free of dysplasia after a mean follow-up of 44 months. Aneuploidy post-PDT was highly predictive for recurrent HGD or cancer with a hazard ratio of 8.2 (1.8–37.8) (log-rank P=0.001). Conclusions: ICDA is accurate for the detection of DNA ploidy abnormalities when compared with FC. After histologically successful PDT, patients with residual aneuploidy are significantly more likely to develop HGD or cancer than those who become diploid. DNA ploidy by ICDA is a valuable prognostic biomarker after ablative therapy.
Collapse
Affiliation(s)
- J M Dunn
- Department of Surgery, National Medical Laser Centre, University College London, 67-73 Riding House Street, London W1W 7EJ, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
PRASAD GANAPATHYA, WANG KENNETHK, HALLING KEVINC, BUTTAR NAVTEJS, WONGKEESONG LOUIS, ZINSMEISTER ALANR, BRANKLEY SHANNONM, BARR FRITCHER EMILYG, WESTRA WYTSKEM, KRISHNADATH KAUSILIAK, LUTZKE LORIS, BORKENHAGEN LYNNS. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology 2008; 135:370-9. [PMID: 18538141 PMCID: PMC3896328 DOI: 10.1053/j.gastro.2008.04.036] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2007] [Revised: 03/31/2008] [Accepted: 04/30/2008] [Indexed: 12/22/2022]
Abstract
BACKGROUND & AIMS Photodynamic therapy (PDT) has been shown to be effective in the treatment of high-grade dysplasia (HGD)/mucosal carcinoma in Barrett's esophagus (BE). Substantial proportions of patients do not respond to PDT or progress to carcinoma despite PDT. The role of biomarkers in predicting response to PDT is unknown. We aimed to determine if biomarkers known to be associated with neoplasia in BE can predict loss of dysplasia in patients treated with ablative therapy for HGD/intramucosal cancer. METHODS Patients with BE and HGD/intramucosal cancer were studied prospectively from 2002 to 2006. Biomarkers were assessed using fluorescence in situ hybridization performed on cytology specimens, for region-specific and centromeric probes. Patients were treated with PDT using cylindric diffusing fibers (wavelength, 630 nm; energy, 200 J/cm fiber). Univariate and multiple variable logistic regression was performed to determine predictors of response to PDT. RESULTS A total of 126 consecutive patients (71 who underwent PDT and 55 patients who did not undergo PDT and were under surveillance, to adjust for the natural history of HGD), were included in this study. Fifty (40%) patients were responders (no dysplasia or carcinoma) at 3 months after PDT. On multiple variable analysis, P16 allelic loss (odds ratio [OR], 0.32; 95% confidence interval [CI], 0.10-0.96) predicted decreased response to PDT. BE segment length (OR, 0.71; 95% CI, 0.59-0.85), and performance of PDT (OR, 7.17; 95% CI, 2.50-20.53) were other independent predictors of loss of dysplasia. CONCLUSIONS p16 loss detected by fluorescence in situ hybridization can help predict loss of dysplasia in patients with BE and HGD/mucosal cancer. Biomarkers may help in the selection of appropriate therapy for patients and improve treatment outcomes.
Collapse
Affiliation(s)
- GANAPATHY A. PRASAD
- Barrett’s Esophagus Unit, Division of Gastroenterology & Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - KENNETH K. WANG
- Barrett’s Esophagus Unit, Division of Gastroenterology & Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - KEVIN C. HALLING
- Department of Laboratory Medicine & Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - NAVTEJ S. BUTTAR
- Barrett’s Esophagus Unit, Division of Gastroenterology & Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - LOUIS–MICHEL WONGKEESONG
- Barrett’s Esophagus Unit, Division of Gastroenterology & Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - ALAN R. ZINSMEISTER
- Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - SHANNON M. BRANKLEY
- Department of Laboratory Medicine & Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - EMILY G. BARR FRITCHER
- Department of Laboratory Medicine & Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - WYTSKE M. WESTRA
- Barrett’s Esophagus Unit, Division of Gastroenterology & Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - KAUSILIA K. KRISHNADATH
- Barrett’s Esophagus Unit, Division of Gastroenterology & Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - LORI S. LUTZKE
- Barrett’s Esophagus Unit, Division of Gastroenterology & Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - LYNN S. BORKENHAGEN
- Barrett’s Esophagus Unit, Division of Gastroenterology & Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
| |
Collapse
|
6
|
|
7
|
Abstract
This article provides a framework for clinicians who are attempting the difficult task of interpreting the Barrett's biomarker literature with the goal of improving care for their patients. Although many articles. including more that 60 proposed biomarkers, have been published on this subject, only a few describe phase 3 and 4 studies that are of interest to the clinical gastroenterologist (Table 1). For year, dysplasia grade has been the sole means of risk stratification for patients with BE, and it likely will continue to be used in the foreseeable future. The current authors believe that dysplasia classification can be valuable using the team management approach and quality controls described previously. Significant problems, however, have emerged in phase 2 through 4 studies of dysplasia that make it imperative for the Barrett's field to incorporate additional biomarkers as they are validated. These problems include poor reproducibility of dysplasia interpretations, poor predictive value for negative, indefinite, and low-grade dysplasia, and inconsistent results for HGD in different centers, all of which makes it virtually impossible to develop national guidelines for surveillance. Some studies have even suggested that endoscopic biopsy surveillance using dysplasia may not be worthwhile. Currently, flow cytometric tetraploidy and aneuploidy have progressed furthest in biomarker validation (see Table 1). With proper handling, endoscopic biopsy specimens can be shipped to reference laboratories that have the instruments, computer analytic methods, and expertise to reproducibly detect tetraploidy and aneuploidy. The results of phase 4 studies indicate that flow cytometry appears to be useful in detecting a subset of patients who do not have HGD and yet have an increased risk of progression to cancer that cannot be identified by dysplasia grade. For many reasons, the authors anticipate that the number of validated biomarkers will increase substantially in the future. Biopsy repositories are now readily available for phase 3 studies that can evaluate and compare biomarkers. There are initiatives for multi-institutional Barrett's Centers of Excellence that could provide rapid progress in biomarker evaluation. In addition to new candidate biomarkers, the human genome project has provided high-throughput methodologies and methods for computer analysis of data, which can provide the volume and quality control required for clinically useful biomarkers. Currently, 17p (p53) LOH has progressed the furthest among molecular biomarkers. The authors do not recommend its routine clinical use at the present time, however. Finally, it is likely that clinicians will want to follow the results of clinical treatment-response studies and epidemiologic studies that evaluate relationship between clinical interventions or environmental risk and protective factors and surrogate endpoints, especially if the endpoints are progessing well along the phases of biomarker validation. These studies are likely to be of clinical interest because they may becoming the basis for randomized clinical trials to prevent cancer in BE.
Collapse
Affiliation(s)
- Brian J Reid
- Division of Human Biology, Fred Hutchinson Cancer Research Center, 100 Fairview Avenue North, Seattle, WA 98109, USA.
| | | | | |
Collapse
|
8
|
Bourré L, Thibaut S, Briffaud A, Rousset N, Eléouet S, Lajat Y, Patrice T. Indirect detection of photosensitizer ex vivo. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY. B, BIOLOGY 2002; 67:23-31. [PMID: 12007464 DOI: 10.1016/s1011-1344(02)00279-8] [Citation(s) in RCA: 96] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Photodynamic therapy induces the production of reactive oxygen species (ROS) within tissues exposed to laser light after administration of a sensitizer. In the context of continuing clinical and commercial development of chemicals with sensitizing properties, a minimally invasive assay is needed to determine the tissue kinetics of fluorescent or non-fluorescent photoreactive drugs. The level of ROS was determined ex vivo from 1 mm3 biopsy samples using 2'-7' dichlorofluorescin diacetate (DCFH-DA), a fluorescent probe which was converted into highly fluorescent dichlorofluorescein (DCF) in the presence of ROS. This assay was tested on meta(tetrahydroxyphenyl)chlorin (m-THPC, FOSCAN), a powerful and fluorescent sensitizer, and bacteriochlorophyll derivative WST09 (TOOKAD), a near-infrared absorbing sensitizer that is only slightly fluorescent. In conjunction with the ROS assay, the tissue accumulation of m-THPC was determined on biopsy samples using an optic fibre spectrofluorometer (OFS). DCF fluorescence was proportional to the level of oxidation induced by horseradish peroxidase used as a control and to the concentration (range: 0-5 microg x ml(-1)) of both selected photosensitizers irradiated in a tube together with DCFH. Regardless of the organ studied, an excellent correlation was found between fluorescence measurement by OFS and ROS determination for m-THPC. m-THPC (2 mg x kg(-1) iv) accumulation in tumour tissues was best after 48 h, and the best signal was obtained in liver. With non-fluorescent WST09 (2 mg x kg(-1)), ROS determination showed the best tumour uptake 48 h after injection, with a tumour/muscle ratio of 5.4. The ROS assay appears to be feasible for determining sensitizer concentration in regular grip biopsy tissue samples.
Collapse
Affiliation(s)
- Ludovic Bourré
- Laboratoire de Photobiologie des Cancers, Département Laser, Hôpital Laënnec, 44093 cedex 01, Nantes, France
| | | | | | | | | | | | | |
Collapse
|
9
|
Andrejevic Blant S, Grosjean P, Ballini JP, Wagnières G, van den Bergh H, Fontolliet C, Monnier P. Localization of tetra(m-hydroxyphenyl)chlorin (Foscan) in human healthy tissues and squamous cell carcinomas of the upper aero-digestive tract, the esophagus and the bronchi: a fluorescence microscopy study. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY. B, BIOLOGY 2001; 61:1-9. [PMID: 11485842 DOI: 10.1016/s1011-1344(01)00148-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
To date, little is known about precise time-dependent distribution and histological localization of tetra(m-hydroxyphenyl)chlorin (mTHPC) in human healthy tissues and squamous cell malignancies in the upper aero-digestive tract. A fluorescence microscopy study was performed on 50 healthy tissue biopsies and on 13 tumors (graded from Tis to T1 SCC) from 30 patients. Tissue samples were taken between 4 h and 11 days following injection of 0.15 mg/kg mTHPC. A fairly comparable distribution pattern in various tissues was observed over time in different patients. Vascular localization of mTHPC fluorescence predominates at a short delay, whereas the dye is essentially located in the tumoral and healthy mucosa after longer delays. A much lower uptake and retention of mTHPC fluorescence was noted in striated muscle and cartilage as compared to neoplastic lesions. No significant selectivity was found between healthy and tumoral mucosa. The obtained data are important to confirm drug-light interval that have been selected for effective PDT for early SCC malignancies while minimizing the risks of over- or under-treatment. The low fluorescence level in striated muscle provides the opportunity to develop interstitial PDT as a treatment modality for invasive SCC of unfavorable locations in the oral cavity or pharynx, such as the base of the tongue.
Collapse
Affiliation(s)
- S Andrejevic Blant
- Institute of Pathology University of Lausanne, CH-1011 Lausanne, Switzerland.
| | | | | | | | | | | | | |
Collapse
|
10
|
|
11
|
Rousset N, Keminon E, Eléouet S, Le Néel T, Auget JL, Vonarx V, Carré J, Lajat Y, Patrice T. Use of alkaline Comet assay to assess DNA repair after m-THPC-PDT. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY. B, BIOLOGY 2000; 56:118-31. [PMID: 11079472 DOI: 10.1016/s1011-1344(00)00053-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Photodynamic therapy (PDT) with Photofrin has already been authorized for certain applications in Japan, the USA and France, and powerful second-generation sensitizers such as meta-(tetrahydroxyphenyl) chlorin (m-THPC) are now being considered for approval. Although sensitizers are likely to localize within the cytoplasm or the plasma membrane, nuclear membrane can be damaged at an early stage of photodynamic reaction, resulting in DNA lesions. Thus, it is of critical importance to assess the safety of m-THPC-PDT, which would be used mainly against early well-differentiated cancers. In this context, m-THPC toxicity and phototoxicity were studied by a colorimetric MTT assay on C6 cells to determine the LD50 (2.5 microg/ml m-THPC for 10 J/cm2 irradiation and 1 microg/ml for 25 J/cm2 irradiation) and PDT doses inducing around 25% cell death. Single-cell electrophoresis (a Comet assay with Tail Moment calculation) was used to evaluate DNA damage and repair in murine glioblastoma C6 cells after LD25 or higher doses for assays of PDT. These results were correlated with m-THPC nuclear distribution by confocal microspectrofluorimetry. m-THPC failed to induce significant changes in the Tail Moment of C6 cells in the absence of light, whereas m-THPC-PDT induced DNA damage immediately after irradiation. The Tail Moment increase was not linear (curve slope being 43 for 0-1 microg/ml m-THPC and 117 for 1-3 microg/ml), but the mean value increased with the light dose (0, 10 or 25 J/cm2) and incubation time (every hour from 1 to 4 h) for an incubation with m-THPC 1 microg/ml. However, cultured murine glioblastoma cells were capable of significant DNA repair after 4 h, and no residual DNA damage was evident after 24-h post-treatment incubation at 37 degrees C. An increase in the light dose appeared to be less genotoxic than an increase in the m-THPC dose for similar toxicities. Our results indicate that m-THPC PDT appears to be a safe treatment since DNA repair seemed to not be impaired and DNA damage occurred only with lethal PDT doses. However, the Comet assay cannot give us the certainty that no mutation, photoadducts or oxidative damage have been developed so this point would be verified with another mutagenicity assay.
Collapse
Affiliation(s)
- N Rousset
- Département Laser, Laboratoire de Photobiologie des Cancers, Hôpital Laënnec, Nantes, France
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Rousset N, Vonarx V, Eléouet S, Carré J, Bourré L, Lajat Y, Patrice T. Cellular distribution and phototoxicity of benzoporphyrin derivative and Photofrin. RESEARCH IN EXPERIMENTAL MEDICINE. ZEITSCHRIFT FUR DIE GESAMTE EXPERIMENTELLE MEDIZIN EINSCHLIESSLICH EXPERIMENTELLER CHIRURGIE 2000; 199:341-57. [PMID: 10945652 DOI: 10.1007/s004339900044] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Photodynamic therapy (PDT) induces cell-membrane damage and alterations in cancer-cell adhesiveness, an important parameter in cancer metastasis. These alterations result from cell sensitivity to photosensitizers and the distribution of photosensitizers in cells. The efficacy of photosensitizers depends on their close proximity to targets and thus on their pharmacokinetics at the cellular level. We studied the cellular distribution of photosensitizers with a confocal microspectrofluorimeter by analysing the fluorescence emitted by benzoporphyrin derivative-monoacid ring A (BPD-MA) and Photofrin relative to their cell sensitivity. Two cancer cell lines of colonic origin, but with different metastatic properties, were used: PROb (progressive) and REGb (regressive). For BPD-MA (1.75 microg/ml), maximal fluorescence intensity (8,300 cts) was reached after 2 h for PROb and after 1 h (4,900 cts) for REGb. For Photofrin (10 microg/ml), maximal fluorescence intensity (467 cts) was reached after 5 h for PROb and after 3 h (404 cts) for REGb. Intracellular studies revealed stronger cytoplasmic than nuclear fluorescence for both BPD and Photofrin. Both of the sensitizers induced a dose-dependent phototoxicity; LD50 with BPD-MA was 93.3 ng/ml for PROb and 71.1 ng/ml for REGb, under an irradiation of 10 J/cm2. With Photofrin, LD50 was 1,270 ng/ml for PROb and 1,200 ng/ml for REGb under an irradiation of 25 J/cm2. The photosensitizer effect within PROb and REGb cancer cells was assessed by incorporation kinetics and toxicity-phototoxicity tests. The intracellular concentration of the photosensitive agent was one important factor in the effectiveness of PDT, but not the only one contributing to the photodynamic effect. In conclusion, this study showed that there was a clear difference between sensitizer uptake and phototoxicity, even in cancer cells of the same origin. This could induce cell-killing heterogeneity in clinics.
Collapse
Affiliation(s)
- N Rousset
- Laboratoire de Photobiologie des Cancers, Département Laser, Nantes, France
| | | | | | | | | | | | | |
Collapse
|
13
|
Hornung R, Walt H, Crompton NEA, Keefe KA, Jentsch B, Perewusnyk G, Haller U, Köchli OR. m-THPC-Mediated Photodynamic Therapy (PDT) Does Not Induce Resistance to Chemotherapy, Radiotherapy or PDT on Human Breast Cancer Cells In Vitro. Photochem Photobiol 1998. [DOI: 10.1111/j.1751-1097.1998.tb02515.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
|
15
|
Kostron H, Obwegeser A, Jakober R. Photodynamic therapy in neurosurgery: a review. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY. B, BIOLOGY 1996; 36:157-68. [PMID: 9002253 DOI: 10.1016/s1011-1344(96)07364-2] [Citation(s) in RCA: 111] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Photodynamic therapy (PDT) has been investigated extensively, both experimentally and clinically, as an adjunctive treatment in the neuro-oncological field. It is based on the more selective accumulation of a photosensitizer in malignant than normal tissue with low systemic toxicity. Subsequent light activation induces photo-oxidation, followed by selective tumour destruction via vascular and direct cellular mechanisms. Malignant brain tumours carry a lethal prognosis with a median survival of 15 months despite surgery, radiotherapy and chemotherapy. PDT is therefore a logical therapeutic concept for brain tumours infiltrating into normal brain. In this review, all the available data on patients treated with haematoporphyrin derivative-mediated PDT are critically analysed. Over 310 patients have been reported in the literature suffering from primary or recurrent malignant brain tumours which were treated with PDT following tumour resection in open clinical phase I/II trials. This number includes 58 patients treated at our own institution. Variations in the treatment protocols make evaluation scientifically difficult; however, there is a clear trend of increased median survival after surgical resection and one single photodynamic treatment. PDT is generally well tolerated and side effects consist of moderate increased intracranial pressure and prolonged skin sensitivity to direct sunlight. The current available data indicate that PDT is a safe treatment, which is well tolerated by the patients and yields an improvement in survival of those with malignant brain tumours. Conclusive information can be expected from controlled clinical trials which are currently being designed. The results raise the hope that PDT will be a valuable addition to the armamentarium for the treatment of cerebral malignancies.
Collapse
Affiliation(s)
- H Kostron
- Department of Neurosurgery, University of Innsbruck, Austria
| | | | | |
Collapse
|
16
|
Blais J, Amirand C, Ballini JP, Debey P, Foultier MT, Patrice T. Photofrin-induced fluorescence in progressive and regressive murine colonic cancer cells: correlation with cell photosensitivity. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY. B, BIOLOGY 1995; 27:225-31. [PMID: 7769535 DOI: 10.1016/1011-1344(94)07081-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Microspectrofluorometry and fluorescence imaging were used to investigate the intracellular fluorescence of two murine colonic cancer cell lines--a progressive cell line (PROb) and a regressive cell line (REGb)--incubated with Photofrin. These two cell lines, which were initially cloned from the same chemically induced colonic murine cancer, differ in their metastatic properties and have been considered as models to mimic the tumoral cell heterogeneity. The fluorescence from cytoplasmic area of cells incubated with Photofrin appeared as a complex emission, with two maxima at 632 and 695 nm assigned to monomer species, and a poorly resolved band around 665 nm assigned to aggregates. The spectral distribution was shown to depend on the incubation time, with an aggregate contribution increasing for extended periods. The amount of Photofrin uptake, as determined from the total fluorescence intensity, was found for PROb to be twice that for REGb. However, the phototoxicities were quite similar for both cell lines, suggesting that drug concentration may not be the only determining factor in photobiological efficiency.
Collapse
Affiliation(s)
- J Blais
- LPCB (Unité de Recherche associée au CNRS 198), Institut Curie, Paris, France
| | | | | | | | | | | |
Collapse
|